Palbociclib Trial | Avocado & Leukemia | Sacituzumab Govitecan for mUCMay 12, 2021 | Oncology Internal Medicine Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial The Journal of Clinical Oncology presents a Rapid Communications summary of the PENELOPE-B trial, a double-blind, placebo‐controlled, phase III study in women with HR+, HER2- primary breast cancer without a pathological complete response after taxane‐containing NACT and at high risk of relapse. With about one-third of women relapsing, palbociclib – a cyclin-dependent kinase 4 and 6 inhibitor – was examined. Read full article Hematology Avocado Discovery May Point to Leukemia Treatment Published recently in Blood, the University of Guelph study highlights a compound only found in avocados – avocatin B – that inhibits the enzyme VLCAD, which is highly prevalent in acute myeloid leukemia (AML). Because the cancer cells rely on this pathway to survive, scientists are hoping to hold human clinical trials to gauge whether avocatin B can be used as a safer, less toxic treatment than traditional chemotherapy. Read full article Internal Medicine TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients w. Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors As a TROP-2-directed antibody-drug conjugate with an SN-38 payload that has shown preliminary activity in metastatic urothelial carcinoma (mUC), sacituzumab govitecan (SG) – brand name Trodelvy –was evaluated and compared to current treatments to gauge whether SG objective response rates (ORRs) and median overall survival (OS) outperform the average of 10% ORR and 7 to 8 months OS. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS